What is AbbVie's forward P/E ratio?

The forward P/E ratio was 15.82 according to Yahoo Finance.

Is AbbVie a good stock to buy?

The bullish thesis suggests the stock is undervalued given its low forward P/E, but risks should be considered.

Is AbbVie (ABBV) a Good Stock to Buy? Bullish Thesis Analysis

AbbVie (ABBV) traded at $225.42 on June 9. Its forward P/E of 15.82 suggests attractive valuation according to a bullish thesis from MoneyShow.

June 11, 2026

2 min read

Source: Insider Monkey

Key Numbers

share price

$225.42

trailing pe

110.50

forward pe

15.82

Waraqati spotted a bullish thesis on AbbVie Inc. (NYSE: ABBV) shared on X.com by @MoneyShow.

AbbVie's share was trading at $225.42 as of June 9, 2026. According to Yahoo Finance, the trailing P/E was 110.50, while the forward P/E stood at just 15.82.

Bullish Thesis Rationale

Bullish analysts argue that the low forward P/E (15.82) reflects strong expectations for future earnings growth, particularly as the company's new product pipeline compensates for patent expirations on key drugs.

Broader Context

Analyst opinions on AbbVie are mixed. Some highlight the strength of the pipeline, while others point to competitive risks. The average price target on TipRanks is around $240.

Conclusion

The bullish thesis relies on attractive forward valuation, but investors should weigh risks from patent cliffs and competition. Further research is recommended before making investment decisions.

Frequently Asked Questions

AbbVie's stock was trading at $225.42 as of June 9, 2026.

Found this useful? Share it

This article was rewritten in Wrqti's editorial style based on information from the original source above. Content is informational only — not investment advice.